MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Cellectar Biosciences Inc

Abierto

0.3 3.45

Resumen

Variación precio

24h

Actual

Mínimo

0.28

Máximo

0.31

Métricas clave

By Trading Economics

Empleados

11

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+222.58% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-3.4M

10M

Apertura anterior

-3.15

Cierre anterior

0.3

Cellectar Biosciences Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

11 dic 2024, 18:44 UTC

Principales Movimientos del Mercado

Cellectar Biosciences Plunges on Pursuit of Strategic Options for Cancer Drug Candidate, 60% Workforce Cut

Comparación entre iguales

Cambio de precio

Cellectar Biosciences Inc Esperado

Precio Objetivo

By TipRanks

222.58% repunte

Estimación a 12 meses

Media 1 USD  222.58%

Máximo 1 USD

Mínimo 1 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Cellectar Biosciences Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

1

Comprar

1

Mantener

0

Vender

Finanzas

$

Acerca de Cellectar Biosciences Inc

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.